• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical & developmental immunology. >Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
【24h】

Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View

机译：妇科癌症中的单克隆抗体：批判性的观点。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

During the last decades, several improvements in treating gynecological malignancies have been achieved. In particular, target therapies, mostly monoclonal antibodies, have emerged as an attractive option for the treatment of these malignancies. In fact, various molecular-targeted agents have been developed for a variety of malignancies with the objective to interfere with a precise tumor associated receptor, essential for cancer cell survival or proliferation, blocking its function, of the cancer cells. Alternatively, monoclonal antibodies have been developed to block immune suppression or enhance functions of immune effector cells. So far, several monoclonal antibodies have been tested for clinical efficacy for the treatment of gynecological cancers. Antibodies against Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) have been used in different neoplasms such as ovarian and cervical cancer. Catumazumab, a bivalent antibody against CD3 and EpCAM, is effective in the treatment of neoplastic ascites. Other antibodies are peculiar for specific cancer-associated antigen such as Oregovomab against CA125 or Farletuzumab against the folate receptor. Here we describe the preclinical and clinical experience gained up to now with monoclonal antibodies in tumors of the female genital tract and trace future therapeutic and research venues.
机译：在过去的几十年中，在治疗妇科恶性肿瘤方面取得了一些进步。特别地，靶向疗法，主要是单克隆抗体，已经成为治疗这些恶性肿瘤的有吸引力的选择。实际上，已经开发了用于各种恶性肿瘤的各种分子靶向剂，目的是干扰精确的肿瘤相关受体，该受体对于癌细胞的存活或增殖是必不可少的，阻断了癌细胞的功能。或者，已开发出单克隆抗体来阻断免疫抑制或增强免疫效应细胞的功能。到目前为止，已经测试了几种单克隆抗体治疗妇科癌症的临床功效。针对血管内皮生长因子（VEGF）和表皮生长因子受体（EGFR）的抗体已用于不同的肿瘤，例如卵巢癌和宫颈癌。 Catumazumab是针对CD3和EpCAM的二价抗体，可有效治疗肿瘤性腹水。其他特定于癌症相关抗原的抗体，例如抗CA125的Oregovomab或抗叶酸受体的Farletuzumab。在这里，我们描述了迄今为止在女性生殖道肿瘤中使用单克隆抗体获得的临床前和临床经验，并追溯了未来的治疗和研究场所。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号